All In Biotech

NDA 215859 · Janssen Pharms

Xarelto

Rivaroxaban · Oral · Factor Xa Inhibitor

Priority reviewDiscontinued

Last checked: Nov 19, 2026Latest source record: Mar 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Dec 20, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

419

129 Phase 3, 75 recruiting

FAERS reports

208,599

174,869 serious, 27,259 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA A. Premature discontinuation of XARELTO increases the risk of thrombotic events Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events. If anticoagulation with XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.3 , 2.4) , Warnings and Precautions (5.1) , and Clinical Studies (14.1) ] . B. Spinal/epidural hematoma Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal...

What it is approved for

From the label in effect Sep 10, 2026.

XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation XARELTO is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of XARELTO and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see Clinical Studies (14.1) ]. 1.2 Treatment of Deep Vein Thrombosis XARELTO is indicated for the treatment of deep vein thrombosis (DVT). 1.3 Treatment of Pulmonary Embolism XARELTO is indicated for the treatment of pulmonary embolism (PE). 1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and/or Pulmonary Embolism XARELTO is...

Mechanism: XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • XARELTO · RIVAROXABAN 1MG/ML · FOR SUSPENSION, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Rivaroxaban" as an intervention, any sponsor and status, largest first.

All 419 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • gastrointestinal haemorrhage21,673
  • off label use8,056
  • haemorrhage7,819
  • dyspnoea7,421
  • epistaxis6,806
  • fatigue6,801
  • death6,190
  • fall6,184
  • pulmonary embolism6,046
  • drug ineffective6,005
  • diarrhoea5,790
  • anaemia5,772

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20074
20083
200952
201055
2011503
20123,861
20137,368
20149,409
201527,674
201629,714
201722,442
201821,010
201921,502
202014,671
202110,008
202210,492
20239,332
20248,319
20257,035
20265,145

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Sep 18, 2026

    Xarelto, For Suspension, 155 mg (NDC 50458-575-01). Business Decision

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xarelto (Rivaroxaban)

2024 spending

$6.23B

Beneficiaries

1,321,019

6,660,246 claims

Per beneficiary

$4,718

$17.68 per unit

View as table
YearSpending
2020$4,701,314,805
2021$5,225,547,772
2022$5,772,682,548
2023$6,309,246,823
2024$6,232,231,840

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,277 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.